

# Edoardo Spina

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3597357/edoardo-spina-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262  
papers

9,603  
citations

57  
h-index

85  
g-index

291  
ext. papers

10,782  
ext. citations

4  
avg, IF

6.07  
L-index

#	Paper	IF	Citations
262	A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 839972	5.6	0
261	Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 808370	5.6	0
260	Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis.. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2022</b> ,	5.5	1
259	Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 846151	5.6	
258	Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 60, 25-37	1.2	0
257	Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2021</b> , 46, 1027-1040	2.2	3
256	P481 Effectiveness and safety profile of biological therapy in inflammatory bowel disease: real life data from an active pharmacovigilance project. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, S470-S471	1.5	
255	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. <i>World Journal of Biological Psychiatry</i> , <b>2021</b> , 22, 561-628	3.8	3
254	Pediatric adverse reactions to antiseizure medications - An analysis of data from the Italian spontaneous reporting system (2001-2019). <i>Epilepsy and Behavior</i> , <b>2021</b> , 119, 107989	3.2	2
253	Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 527-541	3.8	1
252	European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. <i>Journal of Clinical Psychopharmacology</i> , <b>2021</b> , 41, 140-147	1.7	6
251	Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database. <i>Drugs - Real World Outcomes</i> , <b>2021</b> , 1	2.2	2
250	Early atypical injection-site reactions to COVID-19 vaccine: a case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> ,	4.6	3
249	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , <b>2021</b> , 55,	2	11
248	Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RANdomized, participant and rater-blinded, controlled trial (PANDORA trial).. <i>Trials</i> , <b>2021</b> , 22, 896	2.8	0
247	Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents. <i>Pharmaceuticals</i> , <b>2020</b> , 13,	5.2	6
246	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 1457-1463	2.5	23

245	Vortioxetine on Cognition in Schizophrenia: A Pilot Study. <i>Journal of Clinical Psychopharmacology</i> , <b>2020</b> , 40, 381-385	1.7	3
244	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
243	Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , <b>2020</b> , 155, 441-451	0.8	3
242	Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 31-44	5.5	14
241	Clinically relevant drug interactions between statins and antidepressants. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2020</b> , 45, 227-239	2.2	12
240	Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 152	5	5
239	Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1161	5.6	10
238	High mobility group box 1 and markers of oxidative stress in human cord blood. <i>Pediatrics International</i> , <b>2019</b> , 61, 264-270	1.2	7
237	Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2019</b> , 20, 21	2.6	4
236	A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 603-621	3.8	41
235	A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 219-234	3.8	29
234	Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder. <i>Frontiers in Psychiatry</i> , <b>2019</b> , 10, 772	5	9
233	Clozapine Metabolism in East Asians and Caucasians: A Pilot Exploration of the Prevalence of Poor Metabolizers and a Systematic Review. <i>Journal of Clinical Psychopharmacology</i> , <b>2019</b> , 39, 135-144	1.7	29
232	Red Yeast Rice (RYR) supplementation in patients treated with second-generation antipsychotics. <i>Complementary Therapies in Medicine</i> , <b>2018</b> , 37, 167-171	3.5	5
231	Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder. <i>Current Psychiatry Reports</i> , <b>2018</b> , 20, 17	9.1	23
230	Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 350	5.6	57
229	Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 608	5.6	4
228	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 1237-1253	3.8	26

227	Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 493	5	13
226	Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. <i>BioDrugs</i> , <b>2018</b> , 32, 607-617	7.9	7
225	A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 625-639	3.8	26
224	The economic burden of preventable adverse drug reactions: a systematic review of observational studies. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 681-695	4.1	65
223	Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. <i>Psychiatry Research</i> , <b>2017</b> , 247, 257-264	9.9	26
222	Pharmacokinetics of Paliperidone Palmitate in Schizophrenic Patients: Data from a Routine Therapeutic Drug Monitoring Service. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, e50-e51	3.5	2
221	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 965-981	3.8	41
220	Low-Dose of Bergamot-Derived Polyphenolic Fraction (BPF) Did Not Improve Metabolic Parameters in Second Generation Antipsychotics-Treated Patients: Results from a 60-days Open-Label Study. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 197	5.6	9
219	Potentially Clinically Relevant Pharmacodynamic Interactions Between Antiepileptic Drugs and Psychotropic Drugs: An Update. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 5625-5638	3.3	10
218	Clinically Relevant Drug Interactions with Anti-Alzheimer $\beta$ Drugs. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2017</b> , 16, 501-513	2.6	8
217	The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study. <i>CNS Drugs</i> , <b>2016</b> , 30, 1097-1109	6.7	29
216	Efficacy of Antidepressants: Issues Related to Bias in Clinical Trials. <i>Clinical Therapeutics</i> , <b>2016</b> , 38, e2	3.5	1
215	Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. <i>Paediatric Drugs</i> , <b>2016</b> , 18, 319-29	4.2	21
214	Progress and prospects in pharmacogenetics of antidepressant drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 1157-68	5.5	22
213	Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 407-22	5.5	56
212	Genetics of reflex seizures and epilepsies in humans and animals. <i>Epilepsy Research</i> , <b>2016</b> , 121, 47-54	3	43
211	Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. <i>Pharmacological Research</i> , <b>2016</b> , 106, 72-86	10.2	59
210	Rapid versus slow withdrawal of antiepileptic monotherapy in 2-year seizure-free adult patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study. <i>Neurological Sciences</i> , <b>2016</b> , 37, 579-83	3.5	5

209	Management of women with epilepsy: from preconception to post-partum. <i>Archives of Gynecology and Obstetrics</i> , <b>2016</b> , 293, 493-503	2.5	22
208	The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. <i>Current Neuropharmacology</i> , <b>2016</b> , 14, 191-9	7.6	12
207	6-Mer Hyaluronan Oligosaccharides Modulate Neuroinflammation and $\beta$ Synuclein Expression in Neuron-Like SH-SY5Y Cells. <i>Journal of Cellular Biochemistry</i> , <b>2016</b> , 117, 2835-2843	4.7	15
206	EKG parameters in children and adolescents treated with second-generation antipsychotics: a 1-year prospective follow-up study. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, S745-S746	1.2	
205	Mood Stabilizers <b>2016</b> , 177-203		1
204	Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 883-92	5.5	46
203	Clinical applications of CYP genotyping in psychiatry. <i>Journal of Neural Transmission</i> , <b>2015</b> , 122, 5-28	4.3	96
202	P.1.c.012 Open-label study comparing the efficacy and tolerability of aripiprazole and risperidone in the treatment of children with autism spectrum disorder and ADHD. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, S200-S201	1.2	
201	Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 827-30	3.2	7
200	Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder. <i>Neuropsychiatric Disease and Treatment</i> , <b>2015</b> , 11, 1169-74	3.1	10
199	Serenoa repens as an Endocrine Disruptor in a 10-Year-Old Young Girl: A New Case Report. <i>Pharmacology</i> , <b>2015</b> , 96, 41-3	2.3	3
198	Pharmacogenetics of drug-metabolizing enzymes in Italian populations. <i>Drug Metabolism and Personalized Therapy</i> , <b>2015</b> , 30, 107-20	2	6
197	Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 1010-9	3.8	26
196	A molecular pathway analysis informs the genetic background at risk for schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2015</b> , 59, 21-30	5.5	14
195	Therapeutic continuity in the treatment of psychiatric disorders. <i>Global &amp; Regional Health Technology Assessment</i> , <b>2015</b> , 2, GRHTA.5000197	0.2	
194	Evaluation of putative cytotoxic activity of crude extracts from Onopordum acanthium leaves and Spartium junceum flowers against the U-373 glioblastoma cell line. <i>Pakistan Journal of Pharmaceutical Sciences</i> , <b>2015</b> , 28, 1225-32	0.4	6
193	Drug interactions with vortioxetine, a new multimodal antidepressant. <i>Rivista Di Psichiatria</i> , <b>2015</b> , 50, 210-5	3.1	5
192	EKG parameters in children and adolescents treated with aripiprazole and risperidone. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2014</b> , 51, 23-7	5.5	18

191	Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2014</b> , 10, 1457-89	5.5	35
190	Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies. <i>Drug Safety</i> , <b>2014</b> , 37, 501-20	5.1	31
189	Transient global amnesia as a presenting aura or epilepsy?. <i>Headache</i> , <b>2014</b> , 54, 1233-5	4.2	2
188	Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 129-33	1.7	21
187	Acute cerebellar ataxia following meningococcal group C conjugate vaccination. <i>Journal of Child Neurology</i> , <b>2014</b> , 29, 128-30	2.5	7
186	Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2014</b> , 10, 721-46	5.5	70
185	Can valproic acid be an inducer of clozapine metabolism?. <i>Pharmacopsychiatry</i> , <b>2014</b> , 47, 89-96	2	39
184	Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study. <i>BMC Psychiatry</i> , <b>2014</b> , 14, 282	4.2	14
183	Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 620-3	1.7	3
182	Augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label, uncontrolled pilot study. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 491-4	1.7	10
181	Generalized versus partial reflex seizures: a review. <i>Seizure: the Journal of the British Epilepsy Association</i> , <b>2014</b> , 23, 512-20	3.2	58
180	Changes in the prescribing pattern of antidepressant drugs in elderly patients: an Italian, nationwide, population-based study. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 469-78	2.8	25
179	A nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary care. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 227-36	2.8	24
178	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 44, 271-8	5.5	35
177	Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. <i>Drug Safety</i> , <b>2013</b> , 36, 467-79	5.1	53
176	Can zinc depletion play a role in LEV-induced hair loss? Considerations from a case study. <i>Epilepsy and Behavior</i> , <b>2013</b> , 29, 254-5	3.2	2
175	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, S168-S169	1.2	
174	Effects of L'Aquila earthquake on the prescribing pattern of antidepressant and antipsychotic drugs. <i>International Journal of Clinical Pharmacy</i> , <b>2013</b> , 35, 1053-62	2.3	9

173	Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 30-47	3.2	51
172	Preclinical data supporting/refuting the use of Hypericum perforatum in the treatment of depression. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2013</b> , 12, 474-86	2.6	10
171	n-3 fatty acids prevent impairment of neurogenesis and synaptic plasticity in B-cell activating factor (BAFF) transgenic mice. <i>Preventive Medicine</i> , <b>2012</b> , 54 Suppl, S103-8	4.3	16
170	Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 1456-62	4.6	74
169	Clinically significant drug interactions with newer antidepressants. <i>CNS Drugs</i> , <b>2012</b> , 26, 39-67	6.7	104
168	Interactions between antiepileptics and second-generation antipsychotics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2012</b> , 8, 311-34	5.5	45
167	How frequently are contraindicated or warned against combinations of drugs prescribed to patients receiving long-term opioid therapy for chronic pain?. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 453-62	2.6	14
166	Clinically relevant drug interactions in anxiety disorders. <i>Human Psychopharmacology</i> , <b>2012</b> , 27, 239-53	2.3	28
165	Drug dosage individualization based on a random-effects linear model. <i>Journal of Biopharmaceutical Statistics</i> , <b>2012</b> , 22, 463-84	1.3	16
164	Aripiprazole in children with multiple-complex developmental disorder (McDD): a case series. <i>European Psychiatry</i> , <b>2011</b> , 26, 1284-1284	6	
163	Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. <i>Schizophrenia Research</i> , <b>2011</b> , 127, 93-9	3.6	70
162	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 1101-15	5.5	59
161	Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia. <i>Journal of Central Nervous System Disease</i> , <b>2011</b> , 3, 27-41	4.4	11
160	Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. <i>Current Drug Metabolism</i> , <b>2011</b> , 12, 570-7	3.5	59
159	Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. <i>Journal of Clinical Psychopharmacology</i> , <b>2011</b> , 31, 174-9	1.7	84
158	Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. <i>International Clinical Psychopharmacology</i> , <b>2011</b> , 26, 303-10	2.2	28
157	Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. <i>Current Drug Metabolism</i> , <b>2011</b> , 12, 611-20	3.5	95
156	Pharmacogenetics of antidepressants. <i>Frontiers in Pharmacology</i> , <b>2011</b> , 2, 6	5.6	55

155 New antiepileptic drugs **2011**, 38-52

154 Melatonin<sup>R</sup> stimulatory effect on adult hippocampal neurogenesis in mice persists after ovariectomy. *Journal of Pineal Research*, **2011**, 51, 353-60 10.4 27

153 Hypericum perforatum treatment: effect on behaviour and neurogenesis in a chronic stress model in mice. *BMC Complementary and Alternative Medicine*, **2011**, 11, 7 4.7 39

152 Restless Leg Syndrome in ADHD children: levetiracetam as a reasonable therapeutic option. *Brain and Development*, **2011**, 33, 480-6 2.2 21

151 Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. *Journal of Pineal Research*, **2010**, 49, 123-9 10.4 64

150 Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07. *British Journal of Clinical Pharmacology*, **2010**, 70, 514-22 3.8 38

149 Pharmacogenomics of Depression. *Advances in Biological Psychiatry*, **2010**, 58-74 1

148 Reply to Lian et al.. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2010**, 34, 1159 5.5

147 6. Predicting effects of antiepileptics on mood: Clues from knowledge about mechanisms of action. *Epilepsy and Behavior*, **2010**, 17, 580-581 3.2

146 Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders. *Journal of Clinical Psychopharmacology*, **2010**, 30, 634-6 1.7 6

145 Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients. *Nutrition*, **2010**, 26, 677-81 4.8 17

144 Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied. *Journal of Clinical Psychiatry*, **2010**, 71, 957-8; author reply 958-9 4.6 10

143 Newer and older antiepileptic drug use in Southern Italy: a population-based study during the years 2003-2005. *Epilepsy Research*, **2009**, 85, 107-13 3 33

142 Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2009**, 33, 1496-501 5.5 33

141 Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?. *Pharmacological Research*, **2009**, 59, 1-12 10.2 78

140 Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. *Therapeutic Drug Monitoring*, **2009**, 31, 758-63 3.2 33

139 Prescribing pattern of anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003-2005. *Parkinsonism and Related Disorders*, **2008**, 14, 420-5 3.6 25

138 Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2008**, 32, 1453-8 5.5 37

137	Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. <i>Clinical Therapeutics</i> , <b>2008</b> , 30, 1206-27	3.5	269
136	Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2008</b> , 4, 629-38	5.5	91
135	Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. <i>Journal of Psychopharmacology</i> , <b>2008</b> , 22, 39-46	4.6	74
134	Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. <i>Pharmacopsychiatry</i> , <b>2008</b> , 41, 81-91 <sup>2</sup>		70
133	ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 628-33	3.2	51
132	Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. <i>International Journal of Clinical Pharmacy</i> , <b>2008</b> , 30, 44-50		18
131	Further evidence for the association between 5-HT <sub>2C</sub> receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 477-82	2.8	57
130	Therapeutic Drug Monitoring of Quetiapine: Effect of Coadministration with Antiepileptic Drugs in Patients with Psychiatric Disorders. <i>The Open Clinical Chemistry Journal</i> , <b>2008</b> , 1, 17-21		7
129	The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. <i>Expert Opinion on Drug Safety</i> , <b>2007</b> , 6, 651-62	4.1	35
128	Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2007</b> , 16, 552-9	2.6	52
127	Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2007</b> , 16, 422-8	2.6	8
126	Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. <i>European Journal of Neurology</i> , <b>2007</b> , 14, 1317-21	6	70
125	Metabolic drug interactions with newer antipsychotics: a comparative review. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2007</b> , 100, 4-22	3.1	198
124	Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. <i>European Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 233-41	2.8	84
123	Rabeprazole and psychiatric symptoms. <i>Annals of Pharmacotherapy</i> , <b>2007</b> , 41, 1315-7	2.9	12
122	Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. <i>Clinical Neuropharmacology</i> , <b>2007</b> , 30, 107-13	1.4	17
121	Preventing drug interactions with antidepressants in the elderly. <i>Aging Health</i> , <b>2007</b> , 3, 231-243		
120	The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. <i>Schizophrenia Research</i> , <b>2007</b> , 93, 109-116 <sup>36</sup>		84

119	Short-term memory loss associated with rosuvastatin. <i>Pharmacotherapy</i> , <b>2006</b> , 26, 1190-2	5.8	32
118	No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population. <i>Pharmacological Research</i> , <b>2006</b> , 53, 162-5	10.2	13
117	Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 599-602	3.2	37
116	Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 388-93	3.2	31
115	Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. <i>International Clinical Psychopharmacology</i> , <b>2006</b> , 21, 143-51	2.2	43
114	Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy. <i>Pharmacological Research</i> , <b>2005</b> , 51, 211-6	10.2	19
113	Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. <i>Pharmacological Research</i> , <b>2005</b> , 52, 497-501	10.2	13
112	Venlafaxine-induced urinary incontinence resolved after switching to sertraline. <i>Clinical Neuropharmacology</i> , <b>2005</b> , 28, 247-8	1.4	8
111	Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. <i>Epilepsia</i> , <b>2005</b> , 46, 771-4	6.4	35
110	Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2005</b> , 97, 296-301	3.1	84
109	Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 47-53	2.8	48
108	Predictability of metabolic antiepileptic drug interactions <b>2005</b> , 57-92		5
107	Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. <i>Archives of Gerontology and Geriatrics</i> , <b>2004</b> , 291-6	4	42
106	Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2004</b> , 14, 39-47	2.9	75
105	Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. <i>Pharmacological Research</i> , <b>2004</b> , 50, 195-200	10.2	160
104	Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. <i>Clinical Neuropharmacology</i> , <b>2004</b> , 27, 153-6	1.4	159
103	Plasma risperidone concentrations during combined treatment with sertraline. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 386-90	3.2	24
102	The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. <i>International Clinical Psychopharmacology</i> , <b>2004</b> , 19, 71-6	2.2	67

101	Antiepileptic drugs: indications other than epilepsy. <i>Epileptic Disorders</i> , <b>2004</b> , 6, 57-75	1.9	153
100	Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2003</b> , 784, 375-83	3.2	41
99	Metabolic drug interactions with new psychotropic agents. <i>Fundamental and Clinical Pharmacology</i> , <b>2003</b> , 17, 517-38	3.1	138
98	Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. <i>Pharmacological Research</i> , <b>2003</b> , 48, 411-4	10.2	36
97	Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2003</b> , 27, 619-23	5.5	48
96	Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. <i>Neurological Sciences</i> , <b>2002</b> , 23 Suppl 2, S89-90	3.5	38
95	Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. <i>Epilepsia</i> , <b>2002</b> , 43 Suppl 2, 37-44	6.4	91
94	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 702-10	6.1	272
93	Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 419-23	1.7	80
92	Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 616-27	3.2	35
91	Cytochrome P450 polymorphisms and response to antipsychotic therapy. <i>Pharmacogenomics</i> , <b>2002</b> , 3, 201-18	2.6	46
90	Clinically significant drug interactions with antidepressants in the elderly. <i>Drugs and Aging</i> , <b>2002</b> , 19, 299-320	4.7	101
89	Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. <i>Psychopharmacology</i> , <b>2001</b> , 153, 238-43	4.7	101
88	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. <i>Acta Psychiatrica Scandinavica</i> , <b>2001</b> , 104, 173-92	6.5	285
87	Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. <i>British Journal of Clinical Pharmacology</i> , <b>2001</b> , 52, 447-50	3.8	154
86	Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 70, 403-404	6.1	1
85	Newer antipsychotics: comparative review of drug interactions. <i>Expert Review of Neurotherapeutics</i> , <b>2001</b> , 1, 171-82	4.3	11
84	No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 675-8	3.2	18

83	Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 108-9	1.7	30
82	Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 223-7	3.2	95
81	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. <i>Drug Metabolism and Disposition</i> , <b>2001</b> , 29, 1263-8	4	100
80	Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 70, 391-4	6.1	59
79	Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. <i>Biomedical Applications</i> , <b>2000</b> , 746, 173-81		72
78	Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. <i>Psychopharmacology</i> , <b>2000</b> , 148, 83-9	4.7	133
77	CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. <i>European Journal of Clinical Pharmacology</i> , <b>2000</b> , 56, 679-83	2.8	82
76	Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. <i>Pharmacopsychiatry</i> , <b>2000</b> , 33, 213-7	2	59
75	Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 481-5	3.2	113
74	The effect of clozapine on aggressive behaviour in patients with chronic schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>1999</b> , 3, 49-54	2.4	6
73	Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. <i>Epilepsia</i> , <b>1999</b> , 40 Suppl 10, S48-56	6.4	78
72	Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. <i>Psychopharmacology</i> , <b>1999</b> , 147, 300-5	4.7	169
71	Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 341-5	3.2	70
70	No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 577-9	3.2	21
69	Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. <i>Biomedical Applications</i> , <b>1998</b> , 714, 299-308		35
68	No Effect of Citalopram on Plasma Levels of Clozapine, Risperidone and their Active Metabolites in Patients with Chronic Schizophrenia. <i>Clinical Drug Investigation</i> , <b>1998</b> , 16, 393-398	3.2	22
67	Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , <b>1998</b> , 13, 141-5	2.2	57
66	Issues in methodology and applications for therapeutic drug monitoring of fluoxetine and norfluoxetine enantiomers. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 20-4	3.2	7

65	Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 628-30	3.2	29
64	Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. <i>European Journal of Clinical Pharmacology</i> , <b>1997</b> , 51, 395-8	2.8	93
63	Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , <b>1997</b> , 43, 315-8	3.8	34
62	Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 535-8	3.2	23
61	Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. <i>Pharmacological Research</i> , <b>1997</b> , 35, 335-9	10.2	11
60	Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. <i>Clinical Pharmacokinetics</i> , <b>1996</b> , 31, 198-214	6.2	236
59	Phenobarbital induces the 2-hydroxylation of desipramine. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 60-4	3.2	30
58	The effect of carbamazepine on the 2-hydroxylation of desipramine. <i>Psychopharmacology</i> , <b>1995</b> , 117, 413-6	4.7	24
57	Epidemiology and pathoetiology of neurological syndromes with hyperthermia. <i>Functional Neurology</i> , <b>1995</b> , 10, 111-9	2.2	4
56	Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. <i>Epilepsy Research</i> , <b>1994</b> , 19, 245-8	3	24
55	Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications. <i>Pharmacological Research</i> , <b>1994</b> , 29, 121-37	10.2	12
54	CYP2D6-related oxidation polymorphism in Italy. <i>Pharmacological Research</i> , <b>1994</b> , 29, 281-9	10.2	16
53	Clinical pharmacokinetics of fluvoxamine. <i>Clinical Pharmacokinetics</i> , <b>1994</b> , 27, 175-90	6.2	56
52	Iron status in schizophrenic patients with acute neuroleptic-induced dystonic reactions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>1994</b> , 18, 891-8	5.5	4
51	Newer and Older Antidepressants. <i>CNS Drugs</i> , <b>1994</b> , 2, 479-497	6.7	16
50	Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 56, 471-6	6.1	82
49	Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients. <i>Therapeutic Drug Monitoring</i> , <b>1994</b> , 16, 432-4	3.2	2
48	Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. <i>International Clinical Psychopharmacology</i> , <b>1994</b> , 9, 281-5	2.2	75

47	Pharmacokinetic optimisation of tricyclic antidepressant therapy. <i>Clinical Pharmacokinetics</i> , <b>1993</b> , 24, 301-18	6.2	26
46	Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. <i>International Clinical Psychopharmacology</i> , <b>1993</b> , 8, 21-4	2.2	20
45	Carbamazepine coadministration with fluoxetine or fluvoxamine. <i>Therapeutic Drug Monitoring</i> , <b>1993</b> , 15, 247-50	3.2	42
44	Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. <i>Therapeutic Drug Monitoring</i> , <b>1993</b> , 15, 243-6	3.2	126
43	Evidence of chromosomal fragile sites in schizophrenic patients. <i>Annales De Génétique</i> , <b>1993</b> , 36, 132-5		7
42	Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. <i>International Journal of Clinical Pharmacology Research</i> , <b>1993</b> , 13, 167-71		16
41	An endocrinological study of patients with primary cutis verticis gyrata. <i>Acta Dermato-Venereologica</i> , <b>1993</b> , 73, 348-9	2.2	1
40	Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. <i>Acta Psychiatrica Scandinavica</i> , <b>1992</b> , 86, 364-6	6.5	22
39	Interaction between fluvoxamine and imipramine/desipramine in four patients. <i>Therapeutic Drug Monitoring</i> , <b>1992</b> , 14, 194-6	3.2	70
38	Pharmacokinetic interactions between tricyclic antidepressants and other psychotropic drugs in depressed patients. <i>Pharmacological Research</i> , <b>1992</b> , 25, 210-211	10.2	2
37	Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , <b>1992</b> , 34, 85-7	3.8	4
36	Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients. <i>Pharmacological Research</i> , <b>1992</b> , 25, 43-50	10.2	12
35	Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. <i>European Journal of Clinical Pharmacology</i> , <b>1992</b> , 42, 347-8	2.8	50
34	Carbamazepine induced bradycardia--a problem in general or only in susceptible patients? A 24-h long-term electrocardiogram study. <i>Epilepsy Research</i> , <b>1992</b> , 13, 141-5	3	22
33	Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. <i>Therapeutic Drug Monitoring</i> , <b>1991</b> , 13, 109-12	3.2	12
32	Debrisoquine oxidation phenotype during neuroleptic monotherapy. <i>European Journal of Clinical Pharmacology</i> , <b>1991</b> , 41, 467-70	2.8	60
31	Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. <i>Epilepsia</i> , <b>1990</b> , 31, 339-42	6.4	27
30	No effect of thioridazine on plasma concentrations of carbamazepine and its active metabolite carbamazepine-10,11-epoxide. <i>Therapeutic Drug Monitoring</i> , <b>1990</b> , 12, 511-3	3.2	5

29	Prevalence of primary cutis verticis gyrata in a psychiatric population: association with chromosomal fragile sites. <i>Acta Dermato-Venereologica</i> , <b>1990</b> , 70, 483-6	2.2	3
28	Effects of valpromide and viloxazine on the elimination of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. <i>Pharmacological Research</i> , <b>1989</b> , 21, 111-2	10.2	3
27	In vitro inhibition of a polymorphic human liver P-450 isozyme by narcotic analgesics. <i>Anesthesiology</i> , <b>1989</b> , 70, 339-42	4.3	16
26	Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests. <i>Therapeutic Drug Monitoring</i> , <b>1989</b> , 11, 721-3	3.2	6
25	Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators. <i>Psychopharmacology Series</i> , <b>1989</b> , 7, 201-5		3
24	Debrisoquine oxidation in schizophrenic patients treated with neuroleptics. <i>Pharmacological Research Communications</i> , <b>1988</b> , 20, 1103-4		3
23	Inhibition of desipramine 2-hydroxylation by quinidine and quinine. <i>Clinical Pharmacology and Therapeutics</i> , <b>1988</b> , 43, 577-81	6.1	65
22	Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. <i>British Journal of Clinical Pharmacology</i> , <b>1988</b> , 25, 611-3	3.8	23
21	Single-Dose Kinetics of an Enteric-Coated Formulation of Carbamazepine-10,11-epoxide, an Active Metabolite of Carbamazepine. <i>Therapeutic Drug Monitoring</i> , <b>1988</b> , 10, 386-389	3.2	18
20	Alprazolam does not inhibit the metabolism of nortriptyline in depressed patients or inhibit the metabolism of desipramine in human liver microsomes. <i>Therapeutic Drug Monitoring</i> , <b>1988</b> , 10, 231-3	3.2	11
19	Evaluation of tricyclic antidepressant plasma levels by an automated enzyme immunoassay (EMIT) in comparison to a high-performance liquid chromatographic method. <i>Therapeutic Drug Monitoring</i> , <b>1988</b> , 10, 333-9	3.2	5
18	Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. <i>Therapeutic Drug Monitoring</i> , <b>1988</b> , 10, 382-5	3.2	1
17	Tricyclic Antidepressants Analysis by Liquid Chromatography. <i>Journal of Liquid Chromatography and Related Technologies</i> , <b>1987</b> , 10, 223-240		18
16	Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine. <i>Therapeutic Drug Monitoring</i> , <b>1987</b> , 9, 129-33	3.2	9
15	Minor additive inducing effects of phenobarbital on carbamazepine clearance in patients on combined carbamazepine-phenytoin therapy. <i>Therapeutic Drug Monitoring</i> , <b>1987</b> , 9, 117-9	3.2	8
14	Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. <i>Clinical Pharmacology and Therapeutics</i> , <b>1987</b> , 42, 278-82	6.1	39
13	Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype. <i>Clinical Pharmacology and Therapeutics</i> , <b>1987</b> , 41, 314-9	6.1	44
12	Prevalence of cardiac conduction disturbances during carbamazepine treatment: preliminary data. <i>Functional Neurology</i> , <b>1987</b> , 2, 563-7	2.2	1

11	Characterization of desmethylimipramine 2-hydroxylation in human foetal and adult liver microsomes. <i>Acta Pharmacologica Et Toxicologica</i> , <b>1986</b> , 58, 277-81		3
10	Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. <i>Psychopharmacology</i> , <b>1986</b> , 90, 295-8	4.7	15
9	Differential effects of cimetidine and ranitidine on imipramine demethylation and desmethylimipramine hydroxylation by human liver microsomes. <i>European Journal of Clinical Pharmacology</i> , <b>1986</b> , 30, 239-42	2.8	15
8	Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations. <i>Xenobiotica</i> , <b>1986</b> , 16, 391-400	2	18
7	Valproic acid-amitriptyline interaction in man. <i>Therapeutic Drug Monitoring</i> , <b>1986</b> , 8, 382-3	3.2	2
6	IN VITRO COMPETITIVE INHIBITION OF DESIPRAMINE HYDROXYLATION BY ALFENTANIL AND FENTANYL IN HUMAN LIVER MICROSOMES. <i>Anesthesiology</i> , <b>1985</b> , 63, A305	4.3	3
5	Analysis of tricyclic antidepressants in serum and plasma yields similar results. <i>Therapeutic Drug Monitoring</i> , <b>1985</b> , 7, 242-3	3.2	7
4	Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. <i>Biochemical Pharmacology</i> , <b>1985</b> , 34, 2501-5	6	91
3	Desmethylimipramine overdose: nonlinear kinetics in a slow hydroxylator. <i>Therapeutic Drug Monitoring</i> , <b>1985</b> , 7, 239-41	3.2	2
2	Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. <i>Clinical Pharmacology and Therapeutics</i> , <b>1984</b> , 36, 677-82	6.1	90
1	Intra-daily oscillations in dipropylacetic acid plasma levels with two or three daily doses of dipropylacetamide in epileptic patients. <i>Italian Journal of Neurological Sciences</i> , <b>1983</b> , 4, 173-7		